Malaria bi-valent Vaccine: Versatope is currently developing a bi-specific malaria vaccine using our recombinant nano-vesicles (rOMVs), with a SBIR (Small Business Innovation Research) grant from NIH. We are evaluating vaccine candidates for further clinical development that will block initial malaria infection and transmission. The vaccine has the potential for single dose administration, and room temperature stablity, facilitating worldwide deployment. 

Allergy: Versatope’s rOMV platform offers a novel, scalable approach to peanut allergy immunotherapy by using detoxified E. coli nanovesicles to display allergens. These particles act as a potent adjuvant that induces Th1, suppresses Th2-related responses, and provides superior long-term, 100% protection in in vivo models.

Colorectal Cancer  Versatope Therapeutics utilizes genetically engineered recombinant outer membrane vesicles (ROMVs) as a modular platform for precision colorectal cancer therapy. These biogenic nanovesicles are surface-decorated with ligands to target overexpressed clinical biomarkers, ensuring high-payload chemotherapeutic delivery directly to malignant cells. By improving drug bioavailability and providing time-release dosing, Versatope’s technology minimizes off-target toxicity while enhancing treatment efficacy against primary and metastatic tumors.

Inflammatory Bowel Disease:  Versatope leverages its proprietary recombinant nanovesicle platform to treat inflammatory bowel disease (IBD) through site-specific delivery. These probiotic-derived nanovesicles are engineered to carry immuno-modulators and target clinically validated biomarkers, such as mucosal addressins or pro-inflammatory cytokines like TNF-α. By utilizing time-release dosing and enhanced colonic permeability, the platform ensures high local drug concentrations at inflamed tissues while minimizing the systemic side effects common in conventional IBD therapies.